Published in Cardiovasc Drugs Ther on May 01, 1996
Low-voltage-activated ("T-Type") calcium channels in review. J Bioenerg Biomembr (2003) 1.06
T-type calcium channels blockers as new tools in cancer therapies. Pflugers Arch (2014) 0.99
Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med (1972) 4.80
Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med (1972) 3.73
Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science (1989) 2.46
Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation (1992) 2.15
Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension. Am J Cardiol (1975) 2.00
Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation (1990) 1.98
Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem (1986) 1.90
Decreased Beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension (1980) 1.69
Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med (1986) 1.60
Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation. Clin Pharmacol Ther (1982) 1.51
Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension (1990) 1.47
Changes of immunoregulatory cells induced by psychological and physical stress: relationship to plasma catecholamines. Clin Exp Immunol (1984) 1.45
Respective role of humoral factors and blood pressure in aortic remodeling of DOCA hypertensive rats. Am J Hypertens (1996) 1.44
Calcium channels in thrombin-activated human platelet membrane. Nature (1988) 1.39
[Insulin--a side issue or indeed the cause of hypertension?]. Dtsch Med Wochenschr (1991) 1.39
Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res (1990) 1.37
Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am J Pathol (1992) 1.36
Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med (1984) 1.34
Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells. Biochem Biophys Res Commun (1988) 1.32
Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res (1997) 1.25
Induction of growth-related metabolism in human vascular smooth muscle cells by low density lipoprotein. J Biol Chem (1989) 1.23
Endothelium-dependent responses in carotid and renal arteries of normotensive and hypertensive rats. Hypertension (1988) 1.19
Respiratory muscle length measured by sonomicrometry. J Appl Physiol Respir Environ Exerc Physiol (1984) 1.18
Activation of phospholipase A2 by endothelin in cultured vascular smooth muscle cells. Biochem Biophys Res Commun (1989) 1.18
Activation of human peripheral monocytes by angiotensin II. FEBS Lett (1994) 1.16
Importance of endothelium-derived nitric oxide in porcine coronary resistance arteries. Am J Physiol (1991) 1.15
Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: studies in normal subjects. Clin Sci (Lond) (1981) 1.14
Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther (1999) 1.13
Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol (1973) 1.13
5HT-kinetics and sensitivity of human blood platelets: variations with age, gender and platelet number. Thromb Haemost (1988) 1.13
Expression of acidic and basic fibroblast growth factors in human and bovine vascular smooth muscle cells. Growth Factors (1990) 1.12
The place of the calcium antagonist verapamil in antihypertensive therapy. J Cardiovasc Pharmacol (1982) 1.11
Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation (1994) 1.08
Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul (1990) 1.08
The vasodilator potency of atrial natriuretic peptide in man. Circulation (1987) 1.07
Normal renin secretion in hypertensive patients with primarily unilateral chronic hydronephrosis. J Urol (1974) 1.07
Enhancement of calcium influx in human platelets by CGP 28392, a novel dihydropyridine. Biochem Biophys Res Commun (1984) 1.06
Captoril-associated agranulocytosis. Lancet (1980) 1.05
Epidermal growth factor responsiveness in smooth muscle cells from hypertensive and normotensive rats. Hypertension (1989) 1.05
Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone. Am J Cardiol (1973) 1.05
Renovascular hypertension: renin measurements to indicate hypersecretion and contralateral suppression, estimate renal plasma flow, and score for surgical curability. Am J Med (1973) 1.05
Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun (1990) 1.04
Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol (1990) 1.04
Aldosterone excretion. Physiological variations in man measured by radioimmunoassay or double-isotope dilution. Circ Res (1972) 1.04
Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol (1996) 1.03
Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res (1994) 1.03
Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J Appl Physiol (1985) (1996) 1.03
Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol. Circulation (1981) 1.01
Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation (1994) 1.00
Histamine-induced phosphoinositide metabolism in cultured human umbilical vein endothelial cells. Association with thromboxane and prostacyclin release. Biochem Biophys Res Commun (1987) 1.00
Alpha 2 adrenoceptor-mediated vasoconstriction of arteries. Clin Pharmacol Ther (1983) 0.99
Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension (1992) 0.98
Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther (1997) 0.97
Effects of a new long-acting beta-blocker bopindolol (LT 31-200) on blood pressure, plasma catecholamines, renin and cholesterol in patients with arterial hypertension. Eur J Clin Pharmacol (1982) 0.97
Enhanced vasodilatation in essential hypertension by calcium channel blockade with verapamil. Hypertension (1982) 0.97
The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. Am J Med (1975) 0.97
Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens (1994) 0.96
Endothelium-derived relaxing factor and protection against contractions induced by histamine and serotonin in the human internal mammary artery and in the saphenous vein. Circulation (1989) 0.96
Biphasic Ca2+ response of adenylate cyclase. The role of calmodulin in its activation by Ca2+ ions. Eur J Biochem (1986) 0.95
Plasma noradrenaline concentration and alpha-adrenoceptor-mediated vasoconstriction in normotensive and hypertensive man. Clin Sci (Lond) (1981) 0.95
Antihypertensive efficacy of the new long-acting beta-blocker bopindolol as related to age. J Cardiovasc Pharmacol (1983) 0.94
Local angiotensin II generation in the rat heart: role of renin uptake. Circ Res (1998) 0.94
Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. Am J Med (1984) 0.94
Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int (1994) 0.94
Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation (1991) 0.94
Different effects of endothelin-1 on cAMP- and cGMP-mediated vascular relaxation in human arteries and veins: comparison with norepinephrine. J Cardiovasc Pharmacol (1989) 0.93
Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol (1995) 0.93
Phorbol ester promotes a sustained down-regulation of endothelin receptors and cellular responses to endothelin in human vascular smooth muscle cells. Biochem Biophys Res Commun (1990) 0.93
Nailfold microcirculation in normotensive and essential hypertensive subjects, as assessed by video-microscopy. J Hypertens (1992) 0.93
Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study. J Cardiovasc Pharmacol (1987) 0.91
Place of calcium antagonists in antihypertensive therapy: introduction and round-table discussion. J Cardiovasc Pharmacol (1984) 0.90
T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc Drugs Ther (1997) 0.90
Plasma aldosterone-renin interrelationships in various forms of essential hypertension. Studies using a rapid assay of plasma aldosterone. Am J Cardiol (1973) 0.90
Endothelium-derived vasoactive substances: potential role in hypertension, atherosclerosis, and vascular occlusion. J Cardiovasc Pharmacol (1989) 0.90
Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle. Lancet (1992) 0.90
Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. J Cardiovasc Pharmacol (1985) 0.89
Plasma catecholamines and cardiac, renal and peripheral vascular adrenoceptor-mediated responses in different age groups of normal and hypertensive subjects. Clin Exp Hypertens (1980) 0.89
Serum concentration and antihypertensive effect of slow-release verapamil. J Cardiovasc Pharmacol (1982) 0.89
Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension (1993) 0.89
Once a day verapamil in essential hypertension. Br J Clin Pharmacol (1986) 0.88
Functional aspects of vascular tenascin-C expression. J Vasc Res (1995) 0.88
Decreased susceptibility of cultured smooth muscle cells from SHR rats to growth inhibition by heparin. J Cell Physiol (1989) 0.88
Extracellular matrix: differential influence on growth and biosynthesis patterns of vascular smooth muscle cells from SHR and WKY rats. J Cell Physiol (1989) 0.88
Calcium influx blockers in the treatment of essential hypertension. Acta Med Scand Suppl (1984) 0.88
Enhanced responsiveness to angiotensin II in vascular smooth muscle cells from spontaneously hypertensive rats is not associated with alterations in protein kinase C. Hypertension (1989) 0.88
Platelet membrane calmodulin-stimulated calcium-adenosine triphosphatase. Altered activity in essential hypertension. Hypertension (1986) 0.87
Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists. Am J Cardiol (1985) 0.87
Plasma adrenaline and noradrenaline in patients with acute myocardial infarction. Relationship to ventricular arrhythmias of varying severity. Chest (1982) 0.87
Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. J Cardiovasc Pharmacol (1990) 0.87
Calcium antagonists and the second drug for hypertensive therapy. Am J Med (1986) 0.86
Human cardiac plasma concentrations of atrial natriuretic peptide quantified by radioreceptor assay. Biochem Biophys Res Commun (1985) 0.86
Release of nitric oxide from human vascular smooth muscle cells. Biochem Biophys Res Commun (1991) 0.86
Stimulation of autocrine platelet--derived growth factor AA-homodimer and transforming growth factor beta in vascular smooth muscle cells. Biochem Biophys Res Commun (1991) 0.86
Free calcium concentration in platelets closely relates to blood pressure in normal and essentially hypertensive subjects. Hypertension (1984) 0.86
Calcium influx mediated vasoconstriction: studies in patients with mild and moderate essential hypertension. J Hypertens Suppl (1983) 0.85
Changes in cardiovascular responsiveness caused by age and high blood pressure: implications for therapy. J Cardiovasc Pharmacol (1985) 0.85
(-)-Adrenaline-induced, calcium-dependent phosphorylation of proteins in human platelets. J Clin Invest (1985) 0.84
Ligand selectivity of 105 kDa and 130 kDa lipoprotein-binding proteins in vascular-smooth-muscle-cell membranes is unique. Biochem J (1996) 0.84